By Adriano Marchese
Ocugen's drug to treat retina diseases received a rare pediatric disease designation from U.S. regulators.
The biotechnology said Tuesday that the Food and Drug Administration granted the designation to OCU410ST, a gene therapy for the treatment of ABCA4-associated retinopathies, or genetic retinal disorders.
Previously, OCU410ST received orphan drug designations for the treatment of these retinopathies from the FDA and European Medicines Agency.
With the new designation, Ocugen may be awarded a priority review voucher, if the program is reauthorized by the U.S. Congress, the company said, which is a system designed to encourage drug development for rare diseases.
Write to Adriano Marchese at adriano.marchese@wsj.com
(END) Dow Jones Newswires
May 27, 2025 08:18 ET (12:18 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。